C
Cyril Quivoron
Researcher at Institut Gustave Roussy
Publications - 31
Citations - 2632
Cyril Quivoron is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Myeloid leukemia & Myeloid. The author has an hindex of 12, co-authored 26 publications receiving 2196 citations. Previous affiliations of Cyril Quivoron include Université Paris-Saclay & University of Paris-Sud.
Papers
More filters
Journal ArticleDOI
TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis
Cyril Quivoron,Cyril Quivoron,Cyril Quivoron,Lucile Couronné,Lucile Couronné,Lucile Couronné,Véronique Della Valle,Véronique Della Valle,Véronique Della Valle,Cécile K. Lopez,Cécile K. Lopez,Cécile K. Lopez,Isabelle Plo,Isabelle Plo,Isabelle Plo,Orianne Wagner-Ballon,Marcio Do Cruzeiro,François Delhommeau,François Delhommeau,Bertrand Arnulf,Marc-Henri Stern,Lucy A. Godley,Paule Opolon,Hervé Tilly,Eric Solary,Eric Solary,Eric Solary,Yannis Duffourd,Philippe Dessen,Philippe Dessen,Philippe Dessen,Hélène Merle-Béral,Florence Nguyen-Khac,Michaela Fontenay,William Vainchenker,William Vainchenker,William Vainchenker,Christian Bastard,Thomas Mercher,Thomas Mercher,Thomas Mercher,Olivier Bernard,Olivier Bernard,Olivier Bernard +43 more
TL;DR: It is reported that inactivation of Tet2 in mouse perturbs both early and late steps of hematopoiesis including myeloid and lymphoid differentiation in a cell-autonomous manner, endows the cells with competitive advantage, and eventually leads to the development of malignancies.
Journal ArticleDOI
Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation
Fang Wang,Jeremy Travins,Byron DeLaBarre,Virginie Penard-Lacronique,Virginie Penard-Lacronique,Virginie Penard-Lacronique,Stefanie Schalm,Erica Hansen,Kimberly Straley,Andrew Kernytsky,Wei Liu,Camelia Gliser,Hua Yang,Stefan Gross,Erin Artin,Véronique Saada,Elena Mylonas,Elena Mylonas,Elena Mylonas,Cyril Quivoron,Cyril Quivoron,Cyril Quivoron,Janeta Popovici-Muller,Jeffrey O. Saunders,Francesco G. Salituro,Shunqi Yan,Stuart Murray,Wentao Wei,Yi Gao,Lenny Dang,Marion Dorsch,Sam Agresta,David P. Schenkein,Scott A. Biller,Shinsan M. Su,Stéphane de Botton,Stéphane de Botton,Stéphane de Botton,Katharine E. Yen +38 more
TL;DR: Evidence is provided that inhibitors targeting mutant IDH2/R140Q could have potential applications as a differentiation therapy for cancer, and a small molecule, AGI-6780, that potently and selectively inhibits the tumor-associated mutant IDh2/ R140Q is developed.
Journal ArticleDOI
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations
Katharine E. Yen,Jeremy Travins,Fang Wang,Muriel D. David,Muriel D. David,Erin Artin,Kimberly Straley,Anil K. Padyana,Stefan Gross,Byron DeLaBarre,Erica Tobin,Yue Chen,Raj Nagaraja,Sung Choe,Lei Jin,Zenon D. Konteatis,Giovanni Cianchetta,Jeffrey O. Saunders,Francesco G. Salituro,Cyril Quivoron,Cyril Quivoron,Paule Opolon,Olivia Bawa,Véronique Saada,Véronique Saada,Angelo Paci,Sophie Broutin,Olivier Bernard,Olivier Bernard,Stéphane de Botton,Stéphane de Botton,Benoit S. Marteyn,Benoit S. Marteyn,Monika Pilichowska,Yingxia Xu,Cheng Fang,Fan Jiang,Wentao Wei,Shengfang Jin,Lee Silverman,Wei Liu,Hua Yang,Lenny Dang,Marion Dorsch,Virginie Penard-Lacronique,Virginie Penard-Lacronique,Scott A. Biller,Shin-San Michael Su +47 more
TL;DR: It is shown that the targeted inhibitor AG-221 suppresses the mutant IDH2 enzyme in multiple preclinical models and induces differentiation of malignant blasts, supporting its clinical development.
Journal ArticleDOI
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
Janeta Popovici-Muller,Lemieux Rene M,Erin Artin,Jeffrey O. Saunders,Francesco G. Salituro,Jeremy Travins,Giovanni Cianchetta,Zhenwei Cai,Ding Zhou,Cui Dawei,Ping Chen,Kimberly Straley,Erica Tobin,Fang Wang,Muriel D. David,Virginie Penard-Lacronique,Cyril Quivoron,Véronique Saada,Stéphane de Botton,Stefan Gross,Lenny Dang,Hua Yang,Luke Utley,Yue Chen,Hyeryun Kim,Shengfang Jin,Zhiwei Gu,Gui Yao,Zhiyong Luo,Xiaobing Lv,Cheng Fang,Liping Yan,Andrew J. Olaharski,Lee Silverman,Scott A. Biller,Shinsan M. Su,Katharine E. Yen +36 more
TL;DR: AG-120 (ivosidenib), an inhibitor of the IDH1 mutant enzyme that exhibits profound 2-HG lowering in tumor models and the ability to effect differentiation of primary patient AML samples ex vivo is reported.
Journal ArticleDOI
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.
Lynn Quek,Muriel D. David,Alison Kennedy,Marlen Metzner,Michael Amatangelo,Alan Shih,Bilyana Stoilova,Cyril Quivoron,Maël Heiblig,Christophe Willekens,Véronique Saada,Samar Alsafadi,M. S. Vijayabaskar,Andy Peniket,O. Bernard,Sam Agresta,Katharine E. Yen,Kyle J. MacBeth,Eytan M. Stein,George S. Vassiliou,Ross L. Levine,Stéphane de Botton,Anjan Thakurta,Virginie Penard-Lacronique,Paresh Vyas +24 more
TL;DR: Mapping of the clonal structure of bone marrow cells in patients with acute myeloid leukemia treated with the IDH2 inhibitor enasidenib reveals heterogeneity in the cellular differentiation response and in mechanisms of relapse.